Blacks With HCC May Live Longer If Liver Donor Is Black Blacks With HCC May Live Longer If Liver Donor Is Black

For black Americans with hepatocellular carcinoma (HCC) treated with a liver transplant, overall survival beyond 1 year was improved if the liver donor was also a black American.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

This study is registered with, number NCT01953458.FindingsBetween Aug 6, 2012, and Dec 31, 2015, 10 166 patients were eligible for the study. 9895 (97%) patients had available follow-up information and were included in analyses. Median follow-up was 33·4 months (IQR 24·0–40·7). Treatment with direct-acting antivirals was initiated during follow-up in 7344 patients, and 2551 patients remained untreated at the final follow-up visit. During follow-up, 218 patients died (129 treated, 89 untreated), 258 reported hepatocellular carcinoma (187 treated, 71 untreated), and 106 had dec...
Source: The Lancet - Category: General Medicine Source Type: research
ConclusionAnalyses of RNs constructing cirrhotic liver indicated that a variety of genetic aberrations accumulate in the cirrhotic liver before the development of clinically and histologically overt HCC. These aberrations in RNs could provide the basis of tumorigenesis in patients with liver cirrhosis.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Authors: Bürger C, Maschmeier M, Hüsing-Kabar A, Wilms C, Köhler M, Schmidt M, Schmidt HH, Kabar I Abstract Background: Liver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC) and the underlying primary liver disease; however, tumor recurrence is still a major issue. Therefore, the aim of this study was to assess predictors and risk factors for HCC recurrence after LT in patients within and outside the Milan criteria with a special focus on the impact of different bridging strategies. Methods: All patients who underwent LT for HCC between 07/2002 and 09/2016 at the U...
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
Publication date: Available online 7 February 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Becky Yu, Deborah Kwok, Vincent Wai-Sun WongAbstractNon-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide, affecting a quarter of the global adult population. Non-alcoholic steatohepatitis (NASH), the more active form of NAFLD with active hepatic necroinflammation and faster fibrosis progression, has become one of the leading indications for liver transplantation and an important cause of hepatocellular carcinoma in Western countries. Epidemiological studies su...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
CONCLUSION: Survival benefit of LDLT was observed for HCC patients with ITT analysis. Despite a more advanced tumor stage, overall and recurrence-free survival rates were comparable between LDLT and DDLT using PSM analysis. PMID: 30737669 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
ConclusionLSG after LT is technically feasible. Larger series are needed to improve the safety of the procedure in this high-risk population.
Source: Obesity Surgery - Category: Surgery Source Type: research
Authors: Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V Abstract Liver transplantation (LT) is the only potentially curative treatment for selected patients with cirrhosis and hepatocellular carcinoma (HCC) who are not candidates for resection. When the Milan criteria are strictly applied, 75% to 85%of 3- to 4-year actuarial survival rates are achieved, but up to 20% of the patients experience HCC recurrence after transplantation. The Milan criteria are based on the preoperative tumor macromorphology, tumor size and number on computed tomography or magnetic resonance imaging that neither correlate well with ...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
This study aims to analyze living donor liver transplantation for patients with hepatocellular carcinoma and its relationship with hepatitis virus status.MethodsA retrospective analysis of 268 patients who received living donor liver transplantation for hepatocellular carcinoma was performed. Patients were analyzed according to their serologic status of hepatitis virus; clinicopathologic features, operative parameters, and outcomes were also assessed and compared.ResultsTwenty-three patients (8.6%) had hepatocellular carcinoma recurrence following liver transplantation; the most common pattern of recurrence was systemic sp...
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
k N Abstract BACKGROUND: Liver transplantation is the only curative treatment option for patients with end-stage liver disease; however, the 40% decline of available organ donors in recent years in Germany necessitates the optimization of available resources and possibly extending the criteria to older donors. MATERIAL AND METHODS: All 2652 livers made available to the Charité Universitätsmedizin Berlin from 2010 to 2016 were retrospectively analyzed and the clinical outcome of 526 liver transplantations during this time frame were evaluated. RESULTS: The median age of donors of transplanted ...
Source: Der Chirurg - Category: Surgery Authors: Tags: Chirurg Source Type: research
AbstractPurpose of ReviewAutoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) constitute the most frequently observed forms of autoimmune liver diseases. Each of these autoimmune liver diseases might present with cirrhosis at diagnosis, and a significant proportion of patients develop cirrhosis during follow-up. This manuscript provides a review that addresses how to monitor and manage patients with cirrhosis secondary to autoimmune liver diseases.Recent FindingsFor patients with PBC, the farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), is the first approved dru...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
More News: Cancer & Oncology | Carcinoma | Health | Hematology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Transplant Surgery | Transplants | Urology & Nephrology